tldrdailynews.com logo

Novo Nordisk's Profit Warnings and Stock Drop Amid Competition and Guidance Cuts

1 min read
Source: Financial Times
Novo Nordisk's Profit Warnings and Stock Drop Amid Competition and Guidance Cuts
Photo: Financial Times
TL;DR

Novo Nordisk's shares plummeted over 22% after the company issued a profit warning due to intense US market competition and slower-than-expected sales growth for its weight-loss drugs Ozempic and Wegovy, leading to a significant reduction in its full-year sales and profit forecasts, amid ongoing legal actions against copycat drugs.

Topics:top-newsbusiness#business#novo-nordisk#profit-warning#share-price-drop#us-competition#weight-loss-drugs
Share this article
  1. Novo appoints new CEO as it slashes profit forecast  Financial Times
  2. Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance  CNBC
  3. Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook  Yahoo Finance
  4. Novo Nordisk Stock Plummets After Ozempic, Wegovy Maker Cuts U.S. Outlook  Barron's
  5. Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic  MarketWatch

Want the full story? Read the original reporting

Read on Financial Times